Responses
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
SAT0165 Improvements in Patient-Reported Outcomes and Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study
Compose a Response to This Article
Other responses
No responses have been published for this article.